CYP19A1 and female reproductive organ cancer: A recently published prospective study, the PARAGON trial, which examined the role of the aromatase inhibitor anastrozole in relapsed gynecologic cancers, reported a disease control rate of 36% at 3 months and demonstrated a stable quality of life for patients treated with aromatase inhibitors [18,19].